Hematopoietic Cell Transplantation in the Treatment of Germ Cell Tumors

Preauthorization is required and must be obtained through Case Management.

The following protocol contains medical necessity criteria that apply for this service. The criteria are also applicable to services provided in the local Medicare Advantage operating area for those members, unless separate Medicare Advantage criteria are indicated. If the criteria are not met, reimbursement will be denied and the patient cannot be billed. Please note that payment for covered services is subject to eligibility and the limitations noted in the patient’s contract at the time the services are rendered.

<table>
<thead>
<tr>
<th>Populations</th>
<th>Interventions</th>
<th>Comparators</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Individuals: • With previously untreated germ cell tumors</td>
<td>Interventions of interest are: • Autologous hematopoietic cell transplantation as first-line therapy</td>
<td>Comparators of interest are: • Standard-dose chemotherapy • Surgical treatment</td>
<td>Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity</td>
</tr>
<tr>
<td>Individuals: • With relapsed or refractory germ cell tumors</td>
<td>Interventions of interest are: • Autologous hematopoietic cell transplantation</td>
<td>Comparators of interest are: • Standard-dose chemotherapy</td>
<td>Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity</td>
</tr>
<tr>
<td>Individuals: • With germ cell tumors</td>
<td>Interventions of interest are: • Tandem autologous transplantation and sequential high-dose chemotherapy</td>
<td>Comparators of interest are: • Standard-dose chemotherapy • Single autologous hematopoietic cell transplantation</td>
<td>Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity</td>
</tr>
<tr>
<td>Individuals: • With germ cell tumors</td>
<td>Interventions of interest are: • Allogeneic hematopoietic cell transplantation</td>
<td>Comparators of interest are: • Standard-dose chemotherapy • Autologous hematopoietic cell transplantation</td>
<td>Relevant outcomes include: • Overall survival • Disease-specific survival • Treatment-related mortality • Treatment-related morbidity</td>
</tr>
</tbody>
</table>

DESCRIPTION

Therapy for germ cell tumors is generally dictated by several factors, including disease stage, tumor histology, site of tumor primary, and response to chemotherapy. Patients with unfavorable prognostic factors may be candidates for hematopoietic cell transplantation (HCT).

SUMMARY OF EVIDENCE

For individuals who have previously untreated germ cell tumors who receive autologous HCT as first-line therapy, the evidence includes randomized controlled trials (RCTs). Relevant outcomes are overall survival,
disease-specific survival, and treatment-related mortality and morbidity. Results from the RCTs have shown that autologous HCT as initial therapy for germ cell tumors did not significantly improve outcomes compared with alternative therapy (e.g., standard-dose chemotherapy). Study sample sizes were relatively small and might have been underpowered to detect differences between groups. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have relapsed or refractory germ cell tumors who receive autologous HCT, the evidence includes an RCT and several case series. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. The RCT did not find significant differences in outcomes between autologous HCT plus high-dose chemotherapy (HDC) and standard-dose chemotherapy. Case series found three year overall survival rates that ranged from 55% to 60%; these studies lacked comparison groups. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have germ cell tumors who receive tandem autologous transplantation and sequential HDC, the evidence includes an RCT, several retrospective cohort studies, and a comparative effectiveness review. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. The RCT reported a higher rate of treatment-related mortality with sequential HDC compared with single HDC. However, five year survival outcomes did not differ significantly between groups. Overall, the available studies have included heterogeneous patient populations, in different salvage treatment settings (i.e., first vs. subsequent salvage therapy), and have lacked a universally accepted prognostic scoring system to risk-stratify patients. Tandem autologous transplant or transplant with sequential HDC has not shown a benefit in patients with primary mediastinal germ cell tumors. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have germ cell tumors who receive allogeneic HCT, the evidence includes a case report. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. There were no RCTs or nonrandomized comparative studies evaluating allogeneic HCT for germ cell tumors. One 2007 case report has described successful treatment of a refractory mediastinal germ cell tumor with allogeneic HCT. The evidence is insufficient to determine the effects of the technology on health outcomes.

POLICY

Single autologous hematopoietic cell transplantation (HCT) may be considered medically necessary as salvage therapy for germ-cell tumors:

- in patients with favorable prognostic factors that have failed a previous course of conventional-dose salvage chemotherapy; or
- in patients with unfavorable prognostic factors as initial treatment of first relapse (i.e., without a course of conventional-dose salvage chemotherapy) and in patients with platinum-refractory disease. (See Policy Guidelines for prognostic factors.)

Tandem autologous HCT or transplant with sequential high-dose chemotherapy may be considered medically necessary for the treatment of testicular tumors either as salvage therapy or with platinum-refractory disease. Autologous HCT is considered investigational as a component of first-line treatment for germ-cell tumors. Allogeneic HCT is considered investigational to treat germ-cell tumors, including, but not limited to its use as therapy after a prior failed autologous HCT.
POLICY GUIDELINES

Individual transplant facilities may have their own additional requirements or protocols that must be met in order for the patient to be eligible for a transplant at their facility.

The favorable and unfavorable prognostic factors listed below are derived from the current National Comprehensive Cancer Network guidelines and the DeVita et al’s textbook Cancer: Principles and Practice of Oncology (2015, pp. 988-1004).

Patients with favorable prognostic factors include those with a testis or retroperitoneal primary site, a complete response to initial chemotherapy, low levels of serum markers, and low volume disease. Patients with unfavorable prognostic factors are those with an extratesticular primary site, an incomplete response to initial therapy, high levels of serum markers, high-volume disease, or relapsing mediastinal nonseminomatous germ cell tumors.

MEDICARE ADVANTAGE

If a transplant is needed, we arrange to have the transplant center review and decide whether the patient is an appropriate candidate for the transplant.

BACKGROUND

GERM CELL TUMORS

Germ cell tumors are composed primarily of testicular neoplasms as well as ovarian and extragonadal germ cell tumors (no primary tumor in either testis or ovary). Germ cell tumors are classified by their histology, stage, prognosis, and response to chemotherapy.

The most common testicular germ cell tumors are seminomas; all other histologic types are collectively referred to as nonseminomatous tumors. Nonseminomatous tumor types include embryonal cell tumor, yolk sac tumor, and teratomas. Malignant germ cell tumors of ovarian origin are classified as dysgerminomas or nondysgerminomas. Similarly, nondysgerminomas include immature teratomas, embryonal cell tumors, yolk sac tumor, polyembryoma, and mixed germ cell tumors.

Staging

Stage depends on location and extent of the tumor, using the American Joint Committee on Cancer’s TNM system. TNM stages, modified by serum concentrations of markers for tumor burden (S0-3) when available, are grouped by similar prognoses. Markers used for germ cell tumors include human β-chorionic gonadotropin, lactate dehydrogenase, and α-fetoprotein. However, most patients with pure seminoma have normal α-fetoprotein concentrations. For testicular tumors, stages IA to B tumors are limited to the testis (no involved nodes or distant metastases) and no marker elevations (S0); stages IIA to C have increasing size and number of tumor-involved lymph nodes, and at least one marker moderately elevated above the normal range (S1); and stages IIIA to C have distant metastases and/or marker elevations greater than specified thresholds (S2-3).

Germ cell tumors also are divided into good-, intermediate-, or poor-risk categories based on histology, site, extent of primary tumor, and serum marker levels. Good-risk pure seminomas can be at any primary site but are without nonpulmonary visceral metastases or marker elevations. Intermediate-risk pure seminomas have nonpulmonary visceral metastases with or without elevated human chorionic gonadotropin and/or lactate dehydrogenase. There are no poor-risk pure seminomas, but mixed histology tumors and seminomas with elevated α-fetoprotein (due to mixture with nonseminomatous components) are managed as nonseminomatous germ cell tumours.
tumors. Good- and intermediate-risk nonseminomatous germ cell tumors have testicular or retroperitoneal tumors without nonpulmonary visceral metastases, and either S1 (good-risk) or S2 (intermediate) levels of marker elevations. Poor-risk tumors have mediastinal primary tumors, or nonpulmonary visceral metastases, or the highest level (S3) of marker elevations.

Treatment

Therapy for germ cell tumors is generally dictated by stage, risk subgroup, and tumor histology. Testicular cancer is divided into seminomatous and nonseminomatous types for treatment planning because seminomas are more sensitive to radiotherapy. Stage I testicular seminomas may be treated by orchiectomy with or without radiation or single-dose carboplatin adjuvant therapy. Nonseminomatous stage I testicular tumors may be treated with orchiectomy with or without retroperitoneal lymph node dissection. Higher stage disease typically involves treatment that incorporates chemotherapy. First-line chemotherapy for good- and intermediate-risk patients with higher stage disease is usually three or four cycles of a regimen combining cisplatin and etoposide, with or without bleomycin depending on histology and risk group. Chemotherapy is often followed by surgery to remove residual masses. Second-line therapy often consists of combined therapy with ifosfamide/mesna and cisplatin, plus vinblastine, paclitaxel, or etoposide (if not used for first-line treatment). Patients whose tumors are resistant to cisplatin may receive carboplatin-containing regimens. The probability of long-term continuous complete remission diminishes with each successive relapse.

Hematopoietic Cell Transplantation

Hematopoietic cell transplantation (HCT) is a procedure in which hematopoietic stem cells are infused to restore bone marrow function in cancer patients who receive bone-marrow-toxic doses of drugs with or without whole body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or from a donor (allogeneic HCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naive” and thus are associated with a lower incidence of rejection or graft-versus-host disease. Cord blood is discussed in detail in the Placental and Umbilical Cord Blood as a Source of Stem Cells Protocol.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. However, immunologic compatibility between donor and patient is a critical factor for achieving a good outcome of allogeneic HCT. Compatibility is established by typing of human leukocyte antigens using cellular, serologic, or molecular techniques. Human leukocyte antigen refers to the tissue type expressed at the class I and II loci on chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the human leukocyte antigen loci (with the exception of umbilical cord blood).

REGULATORY STATUS

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

Services that are the subject of a clinical trial do not meet our Technology Assessment Protocol criteria and are considered investigational. For explanation of experimental and investigational, please refer to the Technology Assessment Protocol.
It is expected that only appropriate and medically necessary services will be rendered. We reserve the right to conduct prepayment and postpayment reviews to assess the medical appropriateness of the above-referenced procedures. **Some of this protocol may not pertain to the patients you provide care to, as it may relate to products that are not available in your geographic area.**

**REFERENCES**

We are not responsible for the continuing viability of web site addresses that may be listed in any references below.


